EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Asymmetric Dialysis: Truly Unified and Simultaneous Single‐Pass Concentration and Buffer Exchange

Ujwal Patil iD, Michelle Chen, Irina Ramos iD, Jon Coffman

Biotechnology and Bioengineering · 2026

DOI: 10.1002/bit.70218 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2026. Written by Ujwal Patil and 3 co-authors. Institution: Bioprocess Technologies and Engineering, Biopharmaceutical Development, AstraZeneca, Gaithersburg, Maryland, USA. Major MEDLINE topics: Antibodies, Monoclonal, Biological Products. Cited 1 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY 4.0). Funded by: AstraZeneca.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Biopharmaceutical manufacturing has been using ultrafiltration (UF) and diafiltration (DF) for buffer exchange, desalting, and formulation of biologics. The legacy UF/DF is commonly a two‐step batch process that is challenging to integrate into end‐to‐end continuous biomanufacturing. Here, we introduce asymmetric dialysis, a novel one‐step continuous process that combines UF and DF. It works by utilizing asymmetric flow between the inlet and outlet of the retentate and complementary flow of the dialysate solution, achieving product concentration, buffer exchange, and salt removal using a commercially available hollow fiber device. Asymmetric dialysis can achieve product concentrations of 105 (3.8×), 200 (10×), and 64 g/L (9.4×) starting from feed concentrations of 30, 20, and 7 g/L, respectively, with modest pressures of 6–7 psi. The interplay between feed and exchange buffer flow rates was exploited to make the process sustainable by reducing buffer consumption by 75% (25 L/kg mAb) compared to conventional batch UF/DF (100 L/kg, mAb). We successfully processed 7 kg of mAb at 20 g/L feed using 5‐day asymmetric dialysis with a daily productivity of 0.8 kg/m 2 /day to product concentration of 200 g/L. These results demonstrate the potential of asymmetric dialysis, a simple, sustainable, and low‐cost bioprocessing technology for continuous bioprocessing.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalBiological ProductsBuffersUltrafiltrationCricetulus

Author keywords

asymmetric dialysisbioprocess intensificationcontinuous manufacturingcounter‐current dialysisdiafiltrationsingle‐pass bioprocessingultrafiltration

Substances

BuffersAntibodies, MonoclonalBiological Products

Authors and institutions

  • Bioprocess Technologies and Engineering, Biopharmaceutical Development, AstraZeneca, Gaithersburg, Maryland, USA.

ORCID profiles: Ujwal Patil, Irina Ramos

Funding

  • AstraZeneca

Cite

APA

Patil, U., Chen, M., Ramos, I., & Coffman, J. (2026). Asymmetric Dialysis: Truly Unified and Simultaneous Single‐Pass Concentration and Buffer Exchange. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70218

Vancouver

Patil U, Chen M, Ramos I, Coffman J. Asymmetric Dialysis: Truly Unified and Simultaneous Single‐Pass Concentration and Buffer Exchange. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70218

BibTeX
@article{Patil2026,
  author = {Patil, Ujwal and Chen, Michelle and Ramos, Irina and Coffman, Jon},
  title = {Asymmetric Dialysis: Truly Unified and Simultaneous Single‐Pass Concentration and Buffer Exchange},
  journal = {Biotechnology and Bioengineering},
  year = {2026},
  doi = {10.1002/bit.70218}
}
Start for free →